Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Abbott Laboratories
  6. News
  7. Summary
    ABT   US0028241000

ABBOTT LABORATORIES

(ABT)
  Report
Delayed Nyse  -  04:02:47 2023-02-03 pm EST
111.79 USD   -0.41%
01/26Raymond James Adjusts Abbott Laboratories' Price Target to $123 From $109, Keeps Outperform Rating
MT
01/26Abbott Gets FDA Nod for Spinal Cord Stimulation Device to Treat Diabetic Peripheral Neuropathy
MT
01/26Abbott Gets Expanded FDA OK of Proclaim XR in Diabetic Peripheral Neuropathy
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Raymond James Adjusts Abbott Laboratories' Price Target to $109 From $117, Keeps Outperform Rating

10/21/2022 | 08:56am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about ABBOTT LABORATORIES
01/26Raymond James Adjusts Abbott Laboratories' Price Target to $123 From $109, Keeps Outper..
MT
01/26Abbott Gets FDA Nod for Spinal Cord Stimulation Device to Treat Diabetic Peripheral Neu..
MT
01/26Abbott Gets Expanded FDA OK of Proclaim XR in Diabetic Peripheral Neuropathy
DJ
01/26Bernstein Adjusts Price Target on Abbott Laboratories to $132 From $125, Maintains Outp..
MT
01/26FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic P..
PR
01/26Abbott Laboratories Announces the U.S. Food and Drug Administration Approves Its Procla..
CI
01/26Jefferies Adjusts Price Target on Abbott Laboratories to $112 From $105, Maintains Hold..
MT
01/26Barclays Adjusts Price Target on Abbott Laboratories to $125 From $122, Maintains Overw..
MT
01/26Stifel Adjusts Price Target on Abbott Laboratories to $125 From $110, Maintains Buy Rat..
MT
01/26Wolfe Research Adjusts Price Target on Abbott Laboratories to $107 From $92, Maintains ..
MT
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2022 43 227 M - -
Net income 2022 6 848 M - -
Net Debt 2022 4 567 M - -
P/E ratio 2022 28,6x
Yield 2022 1,64%
Capitalization 195 B 195 B -
EV / Sales 2022 4,61x
EV / Sales 2023 4,92x
Nbr of Employees 113 000
Free-Float 87,2%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 111,79 $
Average target price 120,97 $
Spread / Average Target 8,21%
EPS Revisions
Managers and Directors
Robert B. Ford Chairman, President, Chief Executive Officer & COO
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Glenn Fletcher Tilton Independent Director
William A. Osborn Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES2.24%194 914
MEDTRONIC PLC12.69%116 497
BECTON, DICKINSON AND COMPANY-2.29%70 632
DEXCOM, INC.-4.60%41 727
HOYA CORPORATION8.11%38 129
SARTORIUS STEDIM BIOTECH14.94%34 911